JP2016172693A - Serum urate-lowering agent containing rice protein as active ingredient - Google Patents
Serum urate-lowering agent containing rice protein as active ingredient Download PDFInfo
- Publication number
- JP2016172693A JP2016172693A JP2013265887A JP2013265887A JP2016172693A JP 2016172693 A JP2016172693 A JP 2016172693A JP 2013265887 A JP2013265887 A JP 2013265887A JP 2013265887 A JP2013265887 A JP 2013265887A JP 2016172693 A JP2016172693 A JP 2016172693A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- rice
- uric acid
- rice endosperm
- lowering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
本発明は、精白米から抽出されたタンパク質を有効成分とする、血清尿酸値を低下させる技術に関する。 The present invention relates to a technique for lowering serum uric acid levels, which comprises a protein extracted from polished rice as an active ingredient.
尿酸は、ヒトにおいてプリン体の最終代謝産物であり、ＡＴＰの分解や食物中の核酸の代謝で産生され、最終的に尿中に排泄されている。通常、尿酸の産生と排出は均衡しているが、産生量の増加や排出量の減少などの理由で均衡が崩れ血清尿酸値が７ｍｇ／ｄｌを超えると高尿酸血症と定義され、この状態が続くと痛風の発作が起きるリスクが高いとされている。高尿酸血症はかつて日本では稀な病気であったが、食生活の欧米化やアルコール摂取量の増加といった要因によって患者数は年々増加し、現在の患者数は９００万人に達すると推定されている。高尿酸血症は痛風の原因となるだけではなく、痛風腎の原因となることや、心血管・脳血管障害のリスクを上げる可能性があることが指摘されている。高尿酸血症の治療は、痛風発作や合併症を伴わない患者においては食事療法・運動療法が中心となっている。しかし、カロリー制限や運動を継続して行うことは容易なことではない。 Uric acid is the final metabolite of purines in humans, and is produced by the degradation of ATP and the metabolism of nucleic acids in food, and finally excreted in urine. Usually, the production and excretion of uric acid is balanced, but if the balance is lost due to an increase in production or a decrease in excretion, and the serum uric acid level exceeds 7 mg / dl, it is defined as hyperuricemia. If it continues, it is said that the risk of gout attacks is high. Hyperuricemia was once a rare disease in Japan, but the number of patients has increased year by year due to factors such as westernization of diet and increased alcohol intake, and the current number of patients is estimated to reach 9 million. ing. It has been pointed out that hyperuricemia not only causes gout but also causes gout kidneys and may increase the risk of cardiovascular and cerebrovascular disorders. Treatment of hyperuricemia is mainly dietary and exercise therapy in patients without gout attacks or complications. However, it is not easy to continue caloric restriction and exercise.
また、これまでに、血清尿酸値を低下させる薬剤として、尿酸産生抑制薬のアロプリノールや、尿酸排出促進剤のベンズブロマロンなどが実用化されている。しかし、アロプリノールは腎障害を併発している例では副作用のおそれから投与に慎重を要し、尿酸排出促進薬には尿路結石などのリスクが指摘されている。したがって、血中尿酸値を降下させる作用を持ち、普段の食事に簡便にとりいれることができる食品素材があれば、痛風発作や高尿酸血症関連疾患に対する極めて有用な予防・治療法になり得る。 In addition, uric acid production inhibitor allopurinol and uric acid excretion promoting agent benzbromarone have been put to practical use as agents for lowering serum uric acid level. However, allopurinol is required to be administered with caution because it may cause side effects in patients with renal impairment, and uric acid excretion-promoting drugs have been pointed out risks such as urinary calculi. Therefore, if there is a food material that has the effect of lowering the blood uric acid level and can be easily taken into a normal meal, it can be a very useful prevention / treatment method for gout attacks and hyperuricemia-related diseases.
ところで、米胚乳に含まれるタンパク質の主要成分は、易消化性のグルテリン、グロブリン、アルブミンと、難消化性のプロラミンである。米胚乳から抽出されるタンパク質組成物を製造する方法としては、精白米や米粉に耐熱性アミラーゼを作用させ、残存するタンパク質を沈殿として回収する方法（酵素処理米タンパク質）と、精白米や米粉にアルカリ溶液を加えて抽出されるタンパク質を酸沈殿させ、これを回収する方法（アルカリ抽出米タンパク質）が公知である。栄養素としてのタンパク質利用効率は前者に比べて後者で有意に高く、タンパク質利用効率がカゼインに匹敵することが報告されている（非特許文献１）。 By the way, the main components of the protein contained in rice endosperm are easily digestible glutelin, globulin, albumin and indigestible prolamin. As a method of producing a protein composition extracted from rice endosperm, heat-resistant amylase is allowed to act on polished rice or rice flour, and the remaining protein is recovered as a precipitate (enzyme-treated rice protein), A method (alkaline-extracted rice protein) in which protein extracted by adding an alkaline solution is acid precipitated and recovered is known. It has been reported that the protein utilization efficiency as a nutrient is significantly higher in the latter than in the former, and the protein utilization efficiency is comparable to casein (Non-patent Document 1).
米からタンパク質をアルカリ抽出する工程は、米からデンプンを精製する際にタンパク質を除去する工程と類似であるために、アルカリ抽出米タンパク質はデンプン工場の排液から回収することが可能である。 Since the process of alkaline extraction of protein from rice is similar to the process of removing protein when purifying starch from rice, the alkali extracted rice protein can be recovered from the effluent of a starch factory.
本発明の目的は、血中尿酸値降下作用を持ち、日常的に摂取することができる血清尿酸低下剤、および医薬品を提供することにある。 An object of the present invention is to provide a serum uric acid lowering agent and a pharmaceutical product that have a blood uric acid level lowering action and can be taken on a daily basis.
本発明者らは上記の課題を解決すべく種々の検討を重ねた結果、アルカリ抽出米タンパク質にヒトの血清尿酸値を降下させる効果があることを見出し、本発明を完成させるに至った。 As a result of various studies to solve the above problems, the present inventors have found that alkali-extracted rice protein has the effect of lowering human serum uric acid level, and have completed the present invention.
すなわち本発明は、米胚乳タンパク質を有効成分とする、血清尿酸低下剤である。好ましくは、米胚乳タンパク質は、米胚乳よりアルカリにて抽出後に酸で沈殿することで回収されるタンパク質を乾燥させたものである。 That is, the present invention is a serum uric acid lowering agent containing rice endosperm protein as an active ingredient. Preferably, the rice endosperm protein is obtained by drying a protein recovered by extraction from rice endosperm with an alkali and then precipitation with an acid.
さらに、本発明は上記の血清尿酸値降下作用を持つ血清尿酸低下剤を含む、医薬品である。 Furthermore, the present invention is a pharmaceutical comprising the above-described serum uric acid lowering agent having a serum uric acid level lowering action.
本発明の血清尿酸低下剤は米の食経験の豊富さから高い安全性が期待され、日常的に摂取することにより血清尿酸値を低下させることができるために、高尿酸血症や痛風の予防・治療に極めて有効である。 The serum uric acid lowering agent of the present invention is expected to be highly safe due to abundant dietary experience in rice, and since it can lower serum uric acid level by daily intake, it prevents hyperuricemia and gout・ It is extremely effective for treatment.
以下、米胚乳よりアルカリ抽出された米タンパク質を含む組成物を略して、「米胚乳タンパク質」と称する。タンパク質抽出に用いる米の品種はどのようなものであってもよいが、好ましくはジャポニカ種のうるち米である。米胚乳タンパク質は、精白米または米粉等の米胚乳部分を原料としてアルカリにより抽出することができる。精白米を用いる場合には、それをアルカリ溶液に浸漬することでタンパク質の一部が抽出される。浸漬した米を湿式磨砕等により粉砕すると、米の組織中に含まれるタンパク質も抽出されるため、回収率を高めることができる。米粉を用いる場合には、アルカリ溶液中に１時間〜１昼夜浸漬することでタンパク質が高効率で抽出される。 Hereinafter, a composition containing rice protein alkali-extracted from rice endosperm is abbreviated as “rice endosperm protein”. Any variety of rice may be used for protein extraction, but japonica-type glutinous rice is preferable. Rice endosperm protein can be extracted with alkali using rice endosperm such as polished rice or rice flour as a raw material. When using polished rice, a part of protein is extracted by immersing it in an alkaline solution. When the soaked rice is pulverized by wet grinding or the like, the protein contained in the rice tissue is also extracted, so that the recovery rate can be increased. When using rice flour, protein is extracted with high efficiency by soaking in an alkaline solution for 1 hour to 1 day.
抽出に用いるアルカリの濃度は０．１％〜２％であることが好ましく、より好ましくは０．１５〜０．２５％である。抽出されるタンパク質溶液にはアルカリ可溶性の繊維質が多量に含まれていることから、これを目開きの細かい篩や濾布等を用いて除去することが好ましい。タンパク質溶液に塩酸等の酸を加えてｐＨ５〜６に調整することにより、凝集するタンパク質を沈殿として回収することができる。タンパク質溶液をあらかじめ５０℃程度に加熱した後に中和する場合にはｐＨ７でもタンパク質の凝集体が得られ、またこれを８０℃以上に加熱すると凝集体がさらに大きく成長することから、遠心分離を行わずとも篩やフィルタープレス等の濾過によりタンパク質の凝集体を効率良く回収することができる。回収されるタンパク質凝集体を適宜水洗し、これを気流乾燥、流動層乾燥、凍結乾燥等を用いて乾燥することで、米胚乳タンパク質を得ることができる。中和時に加熱を行うことにより、膨潤したタンパク質凝集物が得られ、この凝集物を乾燥することにより、加熱しない場合に比べて保水性や舌触りに優れた米胚乳タンパク質が得られ、より広い用途に利用することができる。 The concentration of alkali used for extraction is preferably 0.1% to 2%, more preferably 0.15 to 0.25%. Since the protein solution to be extracted contains a large amount of alkali-soluble fiber, it is preferably removed using a sieve or a filter cloth having a fine mesh. By adding an acid such as hydrochloric acid to the protein solution and adjusting to pH 5-6, the aggregated protein can be recovered as a precipitate. If the protein solution is pre-heated to about 50 ° C and then neutralized, protein aggregates can be obtained even at pH 7, and if this is heated to 80 ° C or higher, the aggregates grow even larger. At least protein aggregates can be efficiently recovered by filtration using a sieve or filter press. A rice endosperm protein can be obtained by appropriately washing the recovered protein aggregate and drying it using airflow drying, fluidized bed drying, freeze drying, or the like. By heating at the time of neutralization, swollen protein aggregates are obtained. By drying the aggregates, rice endosperm proteins having superior water retention and touch compared to the case without heating can be obtained, and can be used for a wider range of applications. Can be used.
本発明における米胚乳タンパク質は、それのみで血清尿酸値降下剤として用いてもよいが、米胚乳タンパク質を有効成分として賦形剤とともに加工して用いてもよい。 The rice endosperm protein in the present invention may be used alone as a serum uric acid lowering agent, but it may be processed with an excipient as an active ingredient.
本発明の血清尿酸値降下剤を用いる場合、その用量は、患者の年齢・体重・症状・米胚乳タンパク質の加工形態などの要因を加味して適宜決定されることが望ましい。好ましくは、１日あたり純タンパク質として０．５〜２０ｇ、さらに好ましくは３〜１０ｇの摂取が良い。１日あたり純タンパク質として３〜１０ｇを摂取し続けた場合、２週間〜６ヵ月程度で血清尿酸値降下効果が表れることが期待される。 In the case of using the serum uric acid level-lowering agent of the present invention, it is desirable that the dosage is appropriately determined in consideration of factors such as the age, weight, symptoms, and processed form of rice endosperm protein. Preferably, intake of 0.5 to 20 g, more preferably 3 to 10 g as pure protein per day is good. When 3 to 10 g of pure protein is continuously ingested per day, it is expected that a serum uric acid level lowering effect will appear in about 2 weeks to 6 months.
本発明の血清尿酸値降下剤を含有する医薬品（特に高尿酸血症、痛風、痛風腎、心血管、脳血管障害の１以上の治療又は予防用医薬品）を調製する際、他の尿酸産生抑制効果を持つ成分や尿酸排出促進効果を持つ成分を併せて用いても、用いなくてもよい。併せて用いる成分や混合比に特に制限はないが、それぞれの成分の有効量に対して十分な量が望ましい。なお、医薬品の形態は特に限定されないが、経口投与可能な形態であることが好ましい。 When preparing a pharmaceutical (especially one or more therapeutic or preventive pharmaceuticals for hyperuricemia, gout, gout kidney, cardiovascular and cerebrovascular disorders) containing the serum uric acid lowering agent of the present invention, other uric acid production suppression A component having an effect and a component having an effect of promoting uric acid excretion may or may not be used together. Although there is no restriction | limiting in particular in the component and mixing ratio used together, A sufficient quantity is desirable with respect to the effective amount of each component. The form of the drug is not particularly limited, but is preferably a form that can be administered orally.
＜実施例１＞ 臨床試験用米胚乳タンパク質の調製と試験食製造
２５ｋｇのコシヒカリ米粉（新潟製粉株式会社より購入）を１００Ｌの０．２％水酸化ナトリウム溶液に懸濁し、一夜放置した。コクサン社製遠心分離機「Ｈ−１３０Ｉ」に上記懸濁液を約５Ｌ／分の流速で給液した。回転数は１，４００ｒｐｍとした。流出する遠心上清を集め、これを再度同一条件にて遠心分離を行うことにより澱粉粒が除去されたタンパク質抽出液を得た。この抽出液を２８５メッシュ（目開き５３μｍ）の篩を通過させることにより繊維質を除去した。この液を５０℃に加熱し、６Ｎ塩酸を添加してｐＨを７．０に調整した。この液を８０℃で３０分保温することによりタンパク質の凝集体を大きく成長させ、これを冷却した後に２８５メッシュの篩を用いて篩上としてタンパク質を回収した。タンパク質を約５０Ｌの水に懸濁して同様の篩処理を行い、この操作を３回繰り返してタンパク質の水洗を行った。得られた湿タンパク質は絞り袋に入れて圧搾することにより水分を除去し、その後凍結乾燥した。同様の操作を１０回反復し、約７．５ｋｇの米胚乳タンパク質標品を得た。
Example 1 Preparation of Rice Endosperm Protein for Clinical Test and Test Food Production 25 kg of Koshihikari rice flour (purchased from Niigata Flour Milling Co., Ltd.) was suspended in 100 L of 0.2% sodium hydroxide solution and left overnight. The suspension was supplied to a centrifuge “H-130I” manufactured by Kokusan Co., Ltd. at a flow rate of about 5 L / min. The rotation speed was 1,400 rpm. The centrifugal supernatant flowing out was collected and centrifuged again under the same conditions to obtain a protein extract from which the starch granules were removed. The extract was passed through a 285 mesh (aperture 53 μm) sieve to remove the fibrous material. This solution was heated to 50 ° C., and 6N hydrochloric acid was added to adjust the pH to 7.0. The solution was incubated at 80 ° C. for 30 minutes to grow a large protein aggregate. After cooling this, the protein was recovered on a sieve using a 285 mesh sieve. The protein was suspended in about 50 L of water and subjected to the same sieving treatment, and this operation was repeated three times to wash the protein with water. The obtained wet protein was squeezed into a squeezed bag to remove moisture, and then freeze-dried. The same operation was repeated 10 times to obtain about 7.5 kg of rice endosperm protein preparation.
＜実施例２＞
米胚乳タンパク質標品を用いて臨床試験用試験食を製造した（表１参照）。本試験食品１包には純タンパク質として１０ｇの米胚乳タンパク質が含まれるよう、配合を決定した。
<Example 2>
A test meal for clinical trials was produced using the rice endosperm protein preparation (see Table 1). The formulation was determined so that 1 g of the test food contained 10 g of rice endosperm protein as pure protein.
＜実施例３＞
倫理委員会の承認のもとでＢＭＩ ２５ｋｇ／ｍ２以上の肥満者（メタボリックシンドロームを呈する者を含む）を対象に、米胚乳タンパク質を摂取させる臨床試験を実施した。臨床試験は８週間のクロスオーバー形式とし、被験者は２群に分けられ、米胚乳タンパク質配合の試験食または米胚乳タンパク質をカゼインに置き換えた対照試験食を摂取した。各試験食の配合は実施例２にて示された通りであり、前半４週間と後半４週間で、摂取する試験食は入れ替えられた。米胚乳タンパク質配合およびカゼイン配合の試験食それぞれの組成を表１に示す。試験食は１１ｇずつ（米胚乳タンパク質純品としては５ｇ）アルミ包材に充填し、これを１日２回水または湯に溶いて飲用させた。試験期間中は通常の食生活を継続するように指導し、試験食は通常摂取している食品に追加する形とした。
<Example 3>
Under the approval of the Ethics Committee, a clinical trial was conducted in which rice endosperm protein was ingested in obese subjects (including those exhibiting metabolic syndrome) with a BMI of 25 kg / m 2 or more. The clinical study was in an 8-week crossover format, and the subjects were divided into two groups and received a test meal containing rice endosperm protein or a control test meal in which rice endosperm protein was replaced with casein. The composition of each test meal was as shown in Example 2, and the test meals to be ingested were switched between the first 4 weeks and the latter 4 weeks. Table 1 shows the composition of each of the test meals containing rice endosperm protein and casein. Each 11 g of the test meal (5 g as a rice endosperm protein pure product) was filled in an aluminum wrapping material, and this was dissolved in water or hot water twice a day for drinking. Instructions were given to continue the normal diet during the test period, and the test meal was added to the foods normally consumed.
被験者は以下の基準に合致する者とした。
（Ｉ）選択基準
１）ＢＭＩ ２５ｋｇ／ｍ２以上
２）趣旨を理解し（データー使用を含む）、文書同意が得られた者（性別不問）
（ＩＩ）除外基準
１）心、腎、肝臓などに重篤な疾患のある者
２）重症感染症、手術前後、重篤な外傷のある者
３）食物アレルギーを有する者
４）その他、担当医が医学的根拠から研究参画に不適切とした者
選択基準を満たし、除外基準に該当しない男女２４名が被験者となり、１２名ずつ２群に分けられた。被験者のうち１８名（各群９名ずつ）が試験を完遂し、解析の対象になった。
Subjects were those who met the following criteria.
(I) Selection criteria 1) BMI 25kg / m 2 or more 2) Person who understands the purpose (including the use of data) and has obtained document consent (regardless of gender)
(II) Exclusion Criteria 1) Persons with serious illness in heart, kidney, liver, etc. 2) Persons with severe infections, before and after surgery, severe trauma 3) Persons with food allergies 4) Other doctors in charge However, 24 men and women who met the criteria for selecting people who were inappropriate for research participation due to medical reasons and did not meet the exclusion criteria were divided into two groups of 12 people. Of the subjects, 18 (9 in each group) completed the study and were analyzed.
試験開始時、試験食摂取開始後４週目、８週目の合計３回、採血を行い血清尿酸値、脂質代謝マーカー、腎機能マーカーの値を調べた。表２に結果を記載した通り、クロスオーバー試験の前半期間（４週間）において、米胚乳タンパク質摂取群では血清尿酸値の低下傾向（−０．４０ｍｇ／ｄＬ）が認められた。一方で、カゼイン摂取群では血清尿酸値に上昇傾向（＋０．１２ｍｇ／ｄＬ）がみられた。初期値から４週間目の血清尿酸値の変化量を両群で比較すると、両側５％の水準で有意な差があった。本臨床試験に参加した被験者の血清尿酸値の平均は６．３８ｍｇ／ｄＬであり、高尿酸血症の基準値である７．０ｍｇ／ｄＬを下回っている。それにもかかわらず血清尿酸値の低下傾向がみられたことから、米胚乳タンパク質は高尿酸血症に対して治癒的な効果だけでなく予防的な効果をも持つことが示唆された。 At the start of the test, blood was collected for a total of 3 times in the 4th and 8th weeks after the start of test food intake, and the values of serum uric acid level, lipid metabolism marker, and renal function marker were examined. As shown in Table 2, in the first half period (4 weeks) of the crossover test, a decrease in serum uric acid level (−0.40 mg / dL) was observed in the rice endosperm protein intake group. On the other hand, in the casein intake group, the serum uric acid level showed an increasing tendency (+0.12 mg / dL). When the amount of change in serum uric acid level after 4 weeks from the initial value was compared between the two groups, there was a significant difference at the 5% level on both sides. The average serum uric acid level of subjects who participated in this clinical study was 6.38 mg / dL, which is lower than the standard value for hyperuricemia of 7.0 mg / dL. Nonetheless, a tendency to decrease serum uric acid levels was suggested, suggesting that rice endosperm protein has a preventive effect as well as a curative effect on hyperuricemia.
＜実施例４＞
倫理委員会の承認のもとで、維持透析患者９名（男性３名・女性６名）を対象に米胚乳タンパク質を摂取させる臨床試験を実施した。各被験者は、米胚乳タンパク質を含む試験食（実施例２）を２週間に亘り、１日１回水または湯に溶いて飲用した。試験期間中は通常の食生活を継続するように指導し、試験食は通常摂取している食品に追加する形で摂取させた。
<Example 4>
Under the approval of the Ethics Committee, a clinical trial was conducted to ingest rice endosperm protein in 9 maintenance dialysis patients (3 men and 6 women). Each subject drank the test meal (Example 2) containing rice endosperm protein in water or hot water once a day for 2 weeks. During the study period, instruction was given to continue the normal diet, and the test meal was added in addition to the food that was normally consumed.
被験者として、全身状態が安定した低栄養傾向のある成人の維持血液透析患者をリクルートした。選択基準は、血清アルブミン値が３．８ｍｇ／ｄｌ以下を示して低栄養傾向が認められ、かつ本臨床試験の趣旨を理解し文書による同意が得られた者（性別不問）であること、にした。心臓、肝臓等に重篤な疾患のある者、重症感染症、手術前後、重篤な外傷のある者、食物アレルギーを有する者、その他、担当医が研究参画に不適切と判断した者は除外した。 As subjects, we recruited adult maintenance hemodialysis patients with stable general condition and tending to undernutrition. The criteria for selection are those with a serum albumin level of 3.8 mg / dl or less, a tendency toward malnutrition, and an understanding of the purpose of this clinical trial and written consent (gender-independent). did. Excludes persons with serious diseases in the heart, liver, etc., severe infections, before and after surgery, persons with severe trauma, persons with food allergies, and other persons judged inappropriate by the attending physician. did.
試験開始時および米胚乳タンパク質摂取２週間目に採取した血液から、血清尿酸値を測定した。その結果を表３に示す。なお、２番の被験者は試験期間中の感冒により試験食を５日間摂取しなかったため、解析対象からは除外し、９名での解析を行った。摂取２週間目の血清尿酸値の平均値を開始時の数値と比較すると、８．００ｍｇ／ｄＬから７．０９ｍｇ／ｄＬに低下しており、この差は両側５％の水準で有意であった。 Serum uric acid levels were measured from blood collected at the start of the test and 2 weeks after the intake of rice endosperm protein. The results are shown in Table 3. In addition, since the 2nd test subject did not ingest the test meal for 5 days due to the common cold during the test period, the test subjects were excluded from the analysis target and analyzed by 9 subjects. When the mean value of serum uric acid at the second week after ingestion was compared with the value at the start, it decreased from 8.00 mg / dL to 7.09 mg / dL, and this difference was significant at the 5% level on both sides. .
実施例３と比較して、本例では米胚乳タンパク質の摂取量、摂取期間ともに少ないにもかかわらず、本例の方が尿酸値の低下量が平均０．９１ｍｇ／ｄＬと顕著な結果となった。これは、米胚乳タンパク質の尿酸値低下効果は、尿酸値が高い事例でより顕著にあらわれることを示唆するものである。また、本試験の被験者は維持透析患者であるため、尿による尿酸の排出が起こらない。したがって、米胚乳タンパク質の血清尿酸値低下効果には、尿酸の尿中への排出促進以外のメカニズムが働いていることが示唆された。 Compared to Example 3, in this example, although the amount of rice endosperm protein intake and the intake period were both small, the decrease in the uric acid level was 0.91 mg / dL on average in this example. It was. This suggests that the effect of lowering the uric acid level of rice endosperm protein appears more prominently in cases where the uric acid level is high. Moreover, since the test subject is a maintenance dialysis patient, uric acid excretion by urine does not occur. Therefore, it was suggested that a mechanism other than the promotion of uric acid excretion into urine is acting on the serum uric acid level lowering effect of rice endosperm protein.
Claims (3)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013265887A JP2016172693A (en) | 2013-12-24 | 2013-12-24 | Serum urate-lowering agent containing rice protein as active ingredient |
| JP2015554716A JP6088071B2 (en) | 2013-12-24 | 2014-12-08 | Serum uric acid lowering agent containing rice protein as active ingredient |
| PCT/JP2014/082385 WO2015098474A1 (en) | 2013-12-24 | 2014-12-08 | Serum uric acid-reducing agent having rice protein as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013265887A JP2016172693A (en) | 2013-12-24 | 2013-12-24 | Serum urate-lowering agent containing rice protein as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2016172693A true JP2016172693A (en) | 2016-09-29 |
Family
ID=53478339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013265887A Pending JP2016172693A (en) | 2013-12-24 | 2013-12-24 | Serum urate-lowering agent containing rice protein as active ingredient |
| JP2015554716A Active JP6088071B2 (en) | 2013-12-24 | 2014-12-08 | Serum uric acid lowering agent containing rice protein as active ingredient |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015554716A Active JP6088071B2 (en) | 2013-12-24 | 2014-12-08 | Serum uric acid lowering agent containing rice protein as active ingredient |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JP2016172693A (en) |
| WO (1) | WO2015098474A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017186289A (en) * | 2016-04-08 | 2017-10-12 | 亀田製菓株式会社 | Serum uric acid-lowering agent and production method thereof, and method for screening candidate substance that enhances serum uric acid-lowering effect of rice endosperm protein |
| JP6977945B2 (en) * | 2016-05-11 | 2021-12-08 | 亀田製菓株式会社 | A composition for promoting GLP-1 secretion and a method for producing the composition. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005046724A1 (en) * | 2003-11-14 | 2005-05-26 | Human Cell Systems, Inc. | Remedy/preventive for vascular disorders and hypertension and method of screening the same |
| JP2006273840A (en) * | 2005-03-02 | 2006-10-12 | Kameda Seika Co Ltd | Rice protein composition and its use |
| JP2011184313A (en) * | 2010-03-04 | 2011-09-22 | Kyushu Univ | Use of phytoglobulin for treatment of arteriosclerosis |
-
2013
- 2013-12-24 JP JP2013265887A patent/JP2016172693A/en active Pending
-
2014
- 2014-12-08 JP JP2015554716A patent/JP6088071B2/en active Active
- 2014-12-08 WO PCT/JP2014/082385 patent/WO2015098474A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015098474A1 (en) | 2015-07-02 |
| JPWO2015098474A1 (en) | 2017-03-23 |
| JP6088071B2 (en) | 2017-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Suwannaporn et al. | Tolerance and nutritional therapy of dietary fibre from konjac glucomannan hydrolysates for patients with inflammatory bowel disease (IBD) | |
| JP2009502958A (en) | How to treat or manage stress | |
| JP2020172523A (en) | Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system | |
| JP2005068060A (en) | Pharmaceutical composition containing lactoferrin and method for producing processed food containing lactoferrin | |
| JP5271534B2 (en) | Muscle atrophy inhibitor | |
| US9913867B2 (en) | Composition comprising extract of mixture of Undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis | |
| CN105997985A (en) | Application of marihuana extract in preparation of gout treating medicine | |
| CN109620948A (en) | The full nature cell Opsonizing method of high lithemia/gout | |
| JP6088071B2 (en) | Serum uric acid lowering agent containing rice protein as active ingredient | |
| CN109400750A (en) | A kind of preparation method of avenabeta glucosan | |
| WO2017129054A1 (en) | Medicament for treating uremia and proteinuria | |
| CN100467592C (en) | Preparation of highland barley SOD an conditioning food containing highland barley SOD | |
| JP5955236B2 (en) | Blood cresol lowering agent | |
| CN106074464A (en) | Cannabidiol application in preparation treatment gout medicine | |
| CN102389562A (en) | Traditional Chinese medicine composition for treating indigestion in children | |
| JP6139150B2 (en) | Protein nutritional composition | |
| CA2821861C (en) | Composition comprising cinnamon extract | |
| CN109999076A (en) | It is a kind of adjust reverse cholesterol transport Chinese medicine composition and its application | |
| CN103933154A (en) | Traditional Chinese medicine composition for treating gout disease and preparation method thereof | |
| CN110801010A (en) | Composition and health food for preventing and treating constipation | |
| KR20180129692A (en) | Composition for improving of sleep disorder comprising Rhodiola rosea and seed of Nelumbo nucifera | |
| JP5019708B2 (en) | Composition for the treatment and prevention of diabetes | |
| JP6399920B2 (en) | Body fat reducing agent, weight loss promoting agent, blood neutral fat reducing agent and blood free fatty acid reducing agent | |
| CN115444139B (en) | Application of beta-glucan or extract thereof in preparation of medicines for improving hyperuricemia | |
| JP2006213607A (en) | Uric acid value-decreasing agent |